Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: A randomized trial

JAMA

Volumn 309, Issue 13, 2013, Pages 1368-1378

  Fowler, Vance G ^a   Allen, Keith B ^b   Moreira, Edson D ^c,d   Moustafa, Moustafa ^e   Isgro, Frank ^f   Boucher, Helen W ^g   Corey, G Ralph ^a   Carmeli, Yehuda ^h   Betts, Robert ⁱ   Hartzel, Jonathan S ^j   Chan, Ivan S F ^j   McNeely, Tessie B ^j   Kartsonis, Nicholas A ^j   Guris, Dalya ^j   Onorato, Matthew T ^j   Smugar, Steven S ^j   DiNubile, Mark J ^j   Meulen, Ajoke Sobanjo Ter ^j  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Saint Luke's Mid America Heart and Vascular Institute   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e South Carolina Nephrology and Hypertension Center   (United States)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

^g TUFTS MEDICAL CENTER   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; V 710;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CAUSE OF DEATH; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; EXPERIMENTAL THERAPY; FEMALE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; STERNOTOMY; SURGICAL INFECTION; VACCINATION;

EID: 84875655969     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.3010     Document Type: Article

References (44)

1. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007;28(9):1047-1053. (Pubitemid 47345264)
2. Kanafani ZA, Arduino JM, Muhlbaier LH, et al. Incidence of and preoperative risk factors for Staphylococcus aureus bacteremia and chest wound infection after cardiac surgery. Infect Control Hosp Epidemiol. 2009;30(3):242-248.
3. Chen LF, Arduino JM, Sheng S, et al. Epidemiology and outcome of major postoperative infections following cardiac surgery: risk factors and impact of pathogen type. Am J Infect Control. 2012;40(10):963-968.
4. Califf RM, Fowler V Jr, Cabell CH, Corey GR. Novel approaches to clinical trials: device-related infections. Am Heart J. 2004;147(4):599-604. (Pubitemid 38900444)
5. Lee BY, Wiringa AE, Bailey RR, Lewis GJ, Feura J, Muder RR. Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis. Vaccine. 2010;28(12):2465-2471.
6. Kuklin NA, Clark DJ, Secore S, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S aureus sepsis model. Infect Immun. 2006;74(4):2215-2223.
7. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A. 2006;103(45):16942-16947. (Pubitemid 44737357)
8. Kim HK, DeDent A, Cheng AG, et al. IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine. 2010;28(38):6382-6392.
9. Harro C, Betts R, Orenstein W, et al. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin Vaccine Immunol. 2010;17(12):1868-1874.
10. Harro CD, Betts RF, Hartzel JS, et al. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two phase I studies. Vaccine. 2012;30(9):1729-1736.
11. Fowler VG Jr, O'Brien SM, Muhlbaier LH, Corey GR, Ferguson TB, Peterson ED. Clinical predictors of major infections after cardiac surgery. Circulation. 2005;112(9)(suppl):I358-I365. (Pubitemid 41266699)
12. STS Adult Cardiac Surgery Database Risk Model Variables. Version 2.73 http://riskcalc.sts.org/STSWebRiskCalc273/ About%20the%20STS%20Risk%20Calculator%20v2.73.pdf. Accessed July 6, 2012.
13. Garner JS, Jarvis WS, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. APIC Infect Control App Epidemiol. 1996:A1-A20.
14. Jennison C, Turnbull BW. Group Sequential Methods With Applications to Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC Press; 1999.
15. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213-226. (Pubitemid 15055349)
16. Raedler MD, Heyne S, Wagner E, et al. Serologic assay to quantify human immunoglobulin G antibodies to the Staphylococcus aureus iron surface determinant B antigen. Clin Vaccine Immunol. 2009;16(5):739-748.
17. Pancari G, Fan H, Smith S, et al. Frontiers in cellular and infection microbiology: characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB), with functional activity in vitro and in vivo [published online March 20, 2012]. Front Cell Infect Microbiol. 2012;2:36. doi:10.3389/fcimb.2012.00036.
18. Proctor RA. Is there a future for a Staphylococcus aureus vaccine? Vaccine. 2012;30(19):2921-2927.
19. Proctor RA. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis. 2012;54(8):1179-1186.
20. McCarthy AJ, Lindsay JA. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol. 2010;10:173.
21. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346(7):491-496. (Pubitemid 34441740)
22. Deresinski S. Antistaphylococcal vaccines and immunoglobulin therapies. Presented at: 12th International Symposium on Staphylococci and Staphylococcal Infections; Cairns, Australia; September 7-10, 2008. http://jeny.ipro.org/ attachment.php?attachmentid=4692&d=1276005061. Accessed July 6, 2012.
23. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infections. Clin Infect Dis. 2003;36(5):592-598. (Pubitemid 36259564)
24. Reed SD, Friedman JY, Engemann JJ, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol. 2005;26(2):175-183. (Pubitemid 40445023)
25. Kelly-Quintos C, Cavacini LA, Posner MR, Goldmann D, Pier GB. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect Immun. 2006;74(5):2742-2750. (Pubitemid 43672983)
26. Ebert T, Smith S, Pancari G, et al. A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Hum Antibodies. 2010;19(4):113-128.
27. Kelly-Quintos C, Kropec A, Briggs S, Ordonez CL, Goldmann DA, Pier GB. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis. 2005;192(11):2012-2019. (Pubitemid 41681901)
28. Pan K. Understanding original antigenic sin in influenza with a dynamical system. PLoS One. 2011;6(8):e23910.
29. Tang YW. Cytokine pattern is solely influenced by priming vaccine but immunity and disease by both priming and boosting vaccines in mice challenged with respiratory syncytial virus. Virus Res. 2004;99(1):81-87.
30. Reichert T, Chowell G, Nishiura H, Christensen RA, McCullers JA. Does glycosylation as a modifier of original antigenic sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BMC Infect Dis. 2010;10:5.
31. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11(8):532-543.
32. Choi YS, Baek YH, Kang W, et al. Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination. Clin Vaccine Immunol. 2011;18(9):1519-1523.
33. Skurnik D, Merighi M, Grout M, et al. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J Clin Invest. 2010;120(9):3220-3233.
34. Yoong P, Pier GB. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci U S A. 2010;107(5):2241-2246.
35. Gresham HD, Lowrance JH, Caver TE, Wilson BS, Cheung AL, Lindberg FP. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol. 2000;164(7):3713-3722. (Pubitemid 30169827)
36. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888-898.
37. Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol. 2011;11(8):505-518.
38. Niebuhr M, Gathmann M, Scharonow H, et al. Staphylococcal alpha-toxin is a strong inducer of interleukin-17 in humans. Infect Immun. 2011;79(4):1615- 1622.
39. Joshi A, Pancari G, Cope L, et al. Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccin Immunother. 2012;8(3):336-346.
40. Leonardi C, Matheson R, Zachariae C, et al. Antiinterleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-1199.
41. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-1189.
42. Frodermann V, Chau TA, Sayedyahossein S, Toth JM, Heinrichs DE, Madrenas J. A modulatory interleukin-10 response to staphylococcal peptidoglycan prevents Th1/Th17 adaptive immunity to Staphylococcus aureus. J Infect Dis. 2011;204(2):253-262.
43. Moustafa M, Aronoff GR, Chandran C, et al. Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis. Clin Vaccine Immunol. 2012;19(9):1509-1516.
44. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis. 2012;54(4):560-567.